Biotech and Pharma Industry News | BioPharma Dive
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
A Vertex partner — and potential rival — secures $100M to …
Dec 18, 2024 · SiteOne has a complicated relationship with Vertex. Its lead program also regulates NaV1.8, meaning the companies may one day be competitors. Yet they are also working together on a different non-opioid pain drug that targets the “NaV1.7” sodium channel.
NewAmsterdam drug shows ‘unexpected’ signs of protecting the …
Dec 10, 2024 · Obicetrapib’s safety profile, including its potential impact on blood pressure — a concern for drugs of its kind, known as CETP inhibitors — were also comparable to a placebo.A higher percentage of patients in the placebo arm dropped out of the trial due to treatment-related side effects, NewAmsterdam said.
The top biopharma conferences in 2025 | BioPharma Dive
Oct 1, 2024 · American Association of Cancer Research Annual Meeting. April 25 - 30, 2025 Chicago. While the American Society of Clinical Oncology’s meeting often gets billed as the field’s largest conference, AACR has become an equally major gathering for cancer research, particularly earlier-stage findings on new drug mechanisms of action or treatment modalities.
Chroma, Nvelop merge to marry genetic medicine ‘cargo’ to delivery
Dec 11, 2024 · Chroma, Nvelop merge to marry genetic medicine ‘cargo’ to delivery The combined company, which will pair Chroma’s epigenetic editing with Nvelop’s non-viral particles, has raised $75 million from a syndicate of nearly 20 investors.
AbbVie to acquire Roche spinout Nimble in immune drug deal
Dec 13, 2024 · Dive Brief: AbbVie will pay $200 million to acquire privately held Nimble Therapeutics and its pipeline of oral peptide drugs for immune diseases like psoriasis and inflammatory bowel disease, the pharmaceutical company said Friday.; Chief among that pipeline is an oral therapy designed to inhibit a protein called IL-23, the same target of AbbVie’s blockbuster injection Skyrizi.
Editas to lay off staff after search for sickle cell partner comes up ...
Dec 12, 2024 · Dive Brief: Editas Medicine will lay off 180 employees, or about two-thirds of its workforce, over the next six months as part of a broader pivot to focus its drug research on “in vivo” gene editing, the biotechnology company said Thursday.; In October, Editas revealed plans to change course, announcing that it would seek to license out its lead CRISPR medicine for sickle cell disease.
Sanofi’s rare disease drug finds yet another home
Oct 4, 2024 · Enjaymo won U.S. approval in early 2022 after a winding journey. In 2014, the medicine was in development at San Francisco-based iPerian. But that year, Bristol Myers Squibb bought the company for its work in neurodegenerative diseases. iPerian’s programs targeting the immune system were spun out into a new biotechnology firm, True North Therapeutics.
The golden era of GLP-1 drugs: Where we are and what comes next
Sep 23, 2024 · A guidance from the U.S. FDA (draft updated in March 2020) requires data on cardiovascular events in new T2D drug development programs.As a result, dedicated cardiovascular safety trials were implemented. Many demonstrated beneficial effects of GLP-1 RAs on the heart and kidneys in patients with T2D (with and without preexisting conditions), with those effects thought to be largely independent ...
Kalaris to go public via reverse merger with AlloVir
Nov 8, 2024 · TH103 is currently in Phase 1 testing for neovascular age-related macular degeneration, which causes vision loss. Data from that study are expected in the third quarter of next year, and Kalaris believes it has potential to treat other disorders affecting the eye.